AU2022361421A1 - Flavonoid derivatives with gabaa receptor activity and methods of use - Google Patents

Flavonoid derivatives with gabaa receptor activity and methods of use Download PDF

Info

Publication number
AU2022361421A1
AU2022361421A1 AU2022361421A AU2022361421A AU2022361421A1 AU 2022361421 A1 AU2022361421 A1 AU 2022361421A1 AU 2022361421 A AU2022361421 A AU 2022361421A AU 2022361421 A AU2022361421 A AU 2022361421A AU 2022361421 A1 AU2022361421 A1 AU 2022361421A1
Authority
AU
Australia
Prior art keywords
compound
bond
group
groups
occurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022361421A
Other languages
English (en)
Inventor
Eileen CARRY
Jacques Roberge
James E. Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers, The State University of New Jersey
Original Assignee
Rutgers, The State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers, The State University of New Jersey filed Critical Rutgers, The State University of New Jersey
Publication of AU2022361421A1 publication Critical patent/AU2022361421A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022361421A 2021-10-07 2022-10-06 Flavonoid derivatives with gabaa receptor activity and methods of use Pending AU2022361421A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163253341P 2021-10-07 2021-10-07
US63/253,341 2021-10-07
PCT/US2022/045904 WO2023059802A1 (en) 2021-10-07 2022-10-06 Flavonoid derivatives with gabaa receptor activity and methods of use

Publications (1)

Publication Number Publication Date
AU2022361421A1 true AU2022361421A1 (en) 2024-05-09

Family

ID=85803715

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022361421A Pending AU2022361421A1 (en) 2021-10-07 2022-10-06 Flavonoid derivatives with gabaa receptor activity and methods of use

Country Status (7)

Country Link
US (1) US20240398821A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412605A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024538721A (cg-RX-API-DMAC7.html)
CN (1) CN118354770A (cg-RX-API-DMAC7.html)
AU (1) AU2022361421A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233822A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023059802A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS604831B2 (ja) * 1975-10-20 1985-02-06 中外製薬株式会社 4(3h)−キナゾリノン誘導体の製法
US5258478A (en) * 1992-04-27 1993-11-02 Florida State University Low self-absorbing, intrinsically scintillating polymers
GB9521184D0 (en) * 1995-10-17 1995-12-20 Univ Strathclyde Flavonoids
RU2214405C2 (ru) * 1998-02-18 2003-10-20 НьюроСёрч А/С Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US7846915B2 (en) * 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
CA2808680A1 (en) * 2010-08-24 2012-03-01 The Regents Of The University Of California Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
CN106478525A (zh) * 2015-08-28 2017-03-08 南京理工大学 一种合成喹唑酮的方法
CN109879820B (zh) * 2019-02-26 2022-07-19 扬州大学 一种喹唑啉酮杂环化合物的合成方法

Also Published As

Publication number Publication date
JP2024538721A (ja) 2024-10-23
EP4412605A4 (en) 2025-07-30
CN118354770A (zh) 2024-07-16
CA3233822A1 (en) 2023-04-13
US20240398821A1 (en) 2024-12-05
EP4412605A1 (en) 2024-08-14
WO2023059802A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
US20230365542A1 (en) Selective Agonists of 5-HT2A Receptor and Methods of Use
EP3445749B1 (en) Compounds and compositions for treating conditions associated with nlrp activity
CN102958937B (zh) 作为磷酸二酯酶抑制剂的苯并二氧杂环戊烯或苯并二氧杂环庚烯杂环化合物
JP2014055156A (ja) Bclタンパクの結合パートナーとの相互作用を阻害するための化合物および方法
WO2002013812A1 (en) Methods for treating inflammatory diseases
KR20210031931A (ko) 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
WO2024010585A1 (en) Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use
AU2005237607B2 (en) Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
WO2022061196A1 (en) Novel formulations of psilocybin and psilocin compounds as serotonin agonists in combination with 3,4 methylenedioxymethamphetamine (mdma)
JP3939369B2 (ja) β3 −アドレナリン作動薬として作用する{(7S)−7−[(2R)−2−(3−クロロフェニル)−2−ヒドロキシエチルアミノ]−5,6,7,8−テトラヒドロナフタレン−2−イルオキシ)酢酸及びその薬学的に許容されうる塩、並びにそれらが存在する薬学的組成物及び研究室用試薬
US20240398821A1 (en) Flavonoid derivatives with gabaa receptor activity and methods of use
US20220315624A1 (en) Thiostrepton analogs and methods of making and using same
JP2024170613A (ja) Sstr4アゴニスト及びその塩の調製のための方法並びに使用のための用量レジメン
AU2003267557B2 (en) Treatment of dyskinesia
US20220267308A1 (en) Modulators of Excitatory Amino Acid Transporters and Methods Using Same
WO2025217596A1 (en) Substituted 2,3-dihydro-4h-benzo[e][ 1,3] oxazin-4-one compounds and methods of use thereof
WO2023006993A1 (en) Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome
WO2025217249A1 (en) Methods for treating endometriosis and/or other ovary-related diseases and for monitoring treatment
EP2964331B1 (en) Pentacyclic pyridoindolo[b,e]azepine derivatives and uses thereof
EP4642451A2 (en) N-myristoyltransferase inhibitors and methods of use
HK40115276A (en) Flavonoid derivatives with gabaa receptor activity and methods of use
AU2006291059A1 (en) Salicylate and gentisate salts of a piperazine compound
EP4554595A2 (en) Galpha12 inhibitors and methods using same
US20230399303A1 (en) Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same
KR20250129797A (ko) 글루코오스 수치를 조절하기 위한 조성물 및 방법